SMU1: A Protein Implicated in Disease Development (G55234)

Target Name: SMU1

NCBI ID: G55234

SMU1

SMU1: A Protein Implicated in Disease Development

SMU1 (RP11-54K16.3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SMU family of proteins, which are involved in the regulation of cell survival and proliferation. SMU1 has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target or biomarker, SMU1 is of great interest to researchers because of its potential to interfere with the development and progression of these diseases.

SMU1 was first identified in the 1990s as a protein that was expressed in the brain and other tissues. It is a member of the SMU family of proteins, which are characterized by the presence of a specific domain called the nuclear-remodeling domain (NMD). The NMD is a transmembrane domain that is involved in the regulation of protein stability and localization. SMU1 has four known NMDs, which are located at the C-terminus of the protein and are involved in the regulation of protein stability and localization.

SMU1 has been shown to play a role in the development and progression of a variety of diseases. For example, SMU1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells. SMU1 has been shown to interact with the protein tau, which is a component of the neurofibrillary tangles in these diseases. This interaction between SMU1 and tau suggests that SMU1 may be a drug target or biomarker for these diseases.

SMU1 has also been shown to be involved in the development and progression of cancer. For example, SMU1 has been shown to be involved in the development of colon cancer. These cancers are characterized by the formation of tumors in the intestine, and they are a leading cause of cancer-related deaths. SMU1 has been shown to interact with the protein p53, which is a tumor suppressor protein that is involved in the regulation of cell growth and apoptosis. This interaction between SMU1 and p53 suggests that SMU1 may be a drug target or biomarker for cancer.

SMU1 has also been shown to be involved in the development and progression of autoimmune disorders. These disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. SMU1 has been shown to interact with the protein transforming growth factor-beta (TGF-beta), which is a cytokine that is involved in the regulation of cell growth and differentiation. This interaction between SMU1 and TGF-beta suggests that SMU1 may be a drug target or biomarker for autoimmune disorders.

In conclusion, SMU1 (RP11-54K16.3) is a protein that is expressed in various tissues of the body and has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target or biomarker, SMU1 is of great interest to researchers because of its potential to interfere with the development and progression of these diseases. Further research is needed to fully understand the role of SMU1 in these diseases and to develop effective treatments.

Protein Name: SMU1 DNA Replication Regulator And Spliceosomal Factor

Functions: Involved in pre-mRNA splicing as a component of the spliceosome (PubMed:28781166). Regulates alternative splicing of the HSPG2 pre-mRNA (By similarity). Required for normal accumulation of IK (PubMed:24945353). Required for normal mitotic spindle assembly and normal progress through mitosis (By similarity)

The "SMU1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMU1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets